Background Detection of EGFR mutations in tumour tissue is the gold-standard approach to
ascertain if a patient will benefit from treatment with an EGFR tyrosine kinase inhibitor …

背景与目的 表皮生长因子受体 (epidermal growth factor receptor, EGFR)
基因遗传变异可能影响蛋白的功能, 从而影响 EGFR 抑制剂的疗效, 本研究旨在探讨 EGFR …

Purpose: Mutations in epidermal growth factor receptor (EGFR) are strongly predictive of
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …

Introduction The genetic heterogeneity of non-small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) mutations may affect clinical responses and …

BACKGROUND: The objective of this study was to investigate whether polymorphisms in
DNA repair genes affect clinical outcome of never‐smokers with lung adenocarcinoma …

Determinants of interindividual variability in erlotinib pharmacokinetics (PK) and adverse
events remain to be elucidated. This study with 50 Japanese non-small-cell lung cancer …

The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF
receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular …

Objective To compare the clinical efficacies of gefitinib versus paclitaxel/carboplatin in
patients with advanced pulmonary adenocarcinoma. Methods A total of 51 advanced …

OBJECTIVE: Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect
as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who …

Background The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-
TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with …